American Gastroenterological Association Institute Technical Review on the Use of Gastrointestinal Medications in Pregnancy

Gastroenterology

Volumn 131, Issue 1, 2006, Pages 283-311

  Mahadevan, Uma ^a   Kane, Sunanda ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CISAPRIDE; CORTICOSTEROID; FAMOTIDINE; FENTANYL; FLUMAZENIL; GASTROINTESTINAL AGENT; GLUCAGON; HEMOSTATIC AGENT; HEPATITIS VACCINE; IMMUNOSUPPRESSIVE AGENT; LANSOPRAZOLE; LIDOCAINE; NALOXONE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PETHIDINE; PROPOFOL; RANITIDINE; SUCRALFATE; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE PANCREATITIS; ADRENAL INSUFFICIENCY; ANXIETY; ARTHROPATHY; ARTICLE; BIRTH DEFECT; BLEEDING; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BREAST FEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PANCREATITIS; CLEFT LIP; CLEFT PALATE; CLINICAL TRIAL; COMMON BILE DUCT STONE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONSTIPATION; CONVULSION; CORPUS CALLOSUM AGENESIS; CUTIS LAXA; CYANOSIS; DATA BASE; DEHYDRATION; DEVELOPMENTAL DISORDER; DIARRHEA; DISEASE EXACERBATION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG MILK LEVEL; DRUG SAFETY; DUCTUS ARTERIOSUS OBLITERATION; EMBRYOTOXICITY; ENAMEL HYPOPLASIA; ENDOCARDITIS; ENTERITIS; FACE DYSMORPHIA; FETOTOXICITY; FETUS DISTRESS; FETUS MALFORMATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART DISEASE; HUMAN; HYPERALGESIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOTHYROIDISM; INFECTIOUS DIARRHEA; INGUINAL HERNIA; INSOMNIA; INTRAUTERINE GROWTH RETARDATION; IRON DEFICIENCY ANEMIA; IRRITABILITY; ISCHEMIC COLITIS; KIDNEY POLYCYSTIC DISEASE; LIMB MALFORMATION; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW BIRTH WEIGHT; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDICAL SPECIALIST; MENTAL DEFICIENCY; METABOLIC ALKALOSIS; MICROGNATHIA; MOEBIUS SYNDROME; MUSCLE CRAMP; MUSCLE HYPOTONIA; MUSCLE RIGIDITY; NAUSEA; NEONATAL HEMORRHAGE; NEPHROLITHIASIS; NERVOUSNESS; NEUROTOXICITY; NEUTROPENIA; NEWBORN DEATH; NONHUMAN; OLIGOSPERMIA; ORGANOGENESIS; OTOTOXICITY; PAIN; PATIENT CARE; PATIENT MONITORING; PERCEPTION DEAFNESS; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREGNANCY; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PYLORUS STENOSIS; RESPIRATION DEPRESSION; RESTLESSNESS; RETROSPECTIVE STUDY; SCIENCE; SEDATION; SIDE EFFECT; SKELETON MALFORMATION; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENICITY; THYROID DISEASE; TOOTH DISCOLORATION; UROGENITAL TRACT DISEASE; UTERUS CONTRACTION; UTERUS RUPTURE; VIRUS HEPATITIS; VOMITING; WILSON DISEASE; WITHDRAWAL SYNDROME;

EID: 33745757123     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.04.049     Document Type: Article

References (231)

1. Jefferies J.A., Robboy S.J., O'Brien P.C., Bergstralh E.J., Labarthe D.R., Barnes A.B., Noller K.L., Hatab P.A., Kaufman R.H., and Townsend D.E. Structural anomalies of the cervix and vagina in women enrolled in the Diethylstilbestrol Adenosis (DESAD) Project. Am J Obstet Gynecol 148 (1984) 59-66
2. Briggs G.G., Freeman R.K., and Yaffe S.J. Drugs in pregnancy and lactation. 7th ed. (2005), Lippincott, Williams & Wilkins, Philadelphia, PA
3. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 108 (2001) 776-789
4. U.S. Department of Education and Welfare PHS, National Institutes of Health. The Collaborative Study of the National Institute of Neurological Diseases: The Women and Their Pregnancies. DHEW Publication No. (NIH) 73-379, 1972.
5. Schwethelm B., Margolis L.H., Miller C., and Smith S. Risk status and pregnancy outcome among Medicaid recipients. Am J Prev Med 5 (1989) 157-163
6. Fairlie F.M., Marshall L., Walker J.J., and Elbourne D. Intramuscular opioids for maternal pain relief in labour. a randomised controlled trial comparing pethidine with diamorphine. Br J Obstet Gynaecol 106 (1999) 1181-1187
7. Tsui M.H., Ngan Kee W.D., Ng F.F., and Lau T.K. A double blinded randomised placebo-controlled study of intramuscular pethidine for pain relief in the first stage of labour. BJOG 111 (2004) 648-655
8. Barrett J.M., and Boehm F.H. Fetal heart rate responses to meperidine alone and in combination with propiomazine. South Med J 76 (1983) 1480-1483
9. Peiker G., Muller B., Ihn W., and Noschel H. [Excretion of pethidine in mother's milk. (author's transl)]. Zentralbl Gynakol 102 (1980) 537-541
10. Quinn P.G., Kuhnert B.R., Kaine C.J., and Syracuse C.D. Measurement of meperidine and normeperidine in human breast milk by selected ion monitoring. Biomed Environ Mass Spectrom 13 (1986) 133-135
11. Martin L.V., and Jurand A. The absence of teratogenic effects of some analgesics used in anaesthesia. Additional evidence from a mouse model. Anaesthesia 47 (1992) 473-476
12. Fernando R., Bonello E., Gill P., Urquhart J., Reynolds F., and Morgan B. Neonatal welfare and placental transfer of fentanyl and bupivacaine during ambulatory combined spinal epidural analgesia for labour. Anaesthesia 52 (1997) 517-524
13. Morley-Forster P.K., Reid D.W., and Vandeberghe H. A comparison of patient-controlled analgesia fentanyl and alfentanil for labour analgesia. Can J Anaesth 47 (2000) 113-119
14. Nelson K.E., Rauch T., Terebuh V., and D'Angelo R. A comparison of intrathecal fentanyl and sufentanil for labor analgesia. Anesthesiology 96 (2002) 1070-1073
15. Rayburn W., Rathke A., Leuschen M.P., Chleborad J., and Weidner W. Fentanyl citrate analgesia during labor. Am J Obstet Gynecol 161 (1989) 202-206
16. Carrie L.E., O'Sullivan G.M., and Seegobin R. Epidural fentanyl in labour. Anaesthesia 36 (1981) 965-969
17. Lindemann R. Respiratory muscle rigidity in a preterm infant after use of fentanyl during Caesarean section. Eur J Pediatr 157 (1998) 1012-1013
18. Regan J., Chambers F., Gorman W., and MacSullivan R. Neonatal abstinence syndrome due to prolonged administration of fentanyl in pregnancy. BJOG 107 (2000) 570-572
19. Celleno D., Capogna G., Tomassetti M., Costantino P., Di Feo G., and Nisini R. Neurobehavioural effects of propofol on the neonate following elective caesarean section. Br J Anaesth 62 (1989) 649-654
20. Abboud T.K., Zhu J., Richardson M., Peres Da Silva E., and Donovan M. Intravenous propofol vs thiamylal-isoflurane for caesarean section, comparative maternal and neonatal effects. Acta Anaesthesiol Scand 39 (1995) 205-209
21. Cheng Y.J., Wang Y.P., Fan S.Z., and Liu C.C. Intravenous infusion of low dose propofol for conscious sedation in cesarean section before spinal anesthesia. Acta Anaesthesiol Sin 35 (1997) 79-84
22. Gregory M.A., Gin T., Yau G., Leung R.K., Chan K., and Oh T.E. Propofol infusion anaesthesia for caesarean section. Can J Anaesth 37 (1990) 514-520
23. Dailland P., Cockshott I.D., Lirzin J.D., Jacquinot P., Jorrot J.C., Devery J., Harmey J.L., and Conseiller C. Intravenous propofol during cesarean section: placental transfer, concentrations in breast milk, and neonatal effects. A preliminary study. Anesthesiology 71 (1989) 827-834
24. American Academy of Pediatrics Committee on Drugs. Naloxone use in newborns. Pediatrics 65 (1980) 667-669
25. Smotherman W.P., and Robinson S.R. Prenatal experience with milk. fetal behavior and endogenous opioid systems. Neurosci Biobehav Rev 16 (1992) 351-364
26. Safra M.J., and Oakley Jr. G.P. Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet 2 (1975) 478-480
27. Czeizel A. Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. Reprod Toxicol 1 (1987) 183-188
28. Bracken M.B., and Holford T.R. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 58 (1981) 336-344
29. Rothman K.J., Fyler D.C., Goldblatt A., and Kreidberg M.B. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 109 (1979) 433-439
30. Ornoy A., Arnon J., Shechtman S., Moerman L., and Lukashova I. Is benzodiazepine use during pregnancy really teratogenic?. Reprod Toxicol 12 (1998) 511-515
31. Dolovich L.R., Addis A., Vaillancourt J.M., Power J.D., Koren G., and Einarson T.R. Benzodiazepine use in pregnancy and major malformations or oral cleft. meta-analysis of cohort and case-control studies. BMJ 317 (1998) 839-843
32. Wesson D.R., Camber S., Harkey M., and Smith D.E. Diazepam and desmethyldiazepam in breast milk. J Psychoactive Drugs 17 (1985) 55-56
33. Bland B.A., Lawes E.G., Duncan P.W., Warnell I., and Downing J.W. Comparison of midazolam and thiopental for rapid sequence anesthetic induction for elective cesarean section. Anesth Analg 66 (1987) 1165-1168
34. Celleno D., Capogna G., Emanuelli M., Varrassi G., Muratori F., Costantino P., and Sebastiani M. Which induction drug for cesarean section? A comparison of thiopental sodium, propofol, and midazolam. J Clin Anesth 5 (1993) 284-288
35. Cappell M.S., Colon V.J., and Sidhom O.A. A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci 41 (1996) 2353-2361
36. Cappell M.S., Colon V.J., and Sidhom O.A. A study of eight medical centers of the safety and clinical efficacy of esophagogastroduodenoscopy in 83 pregnant females with follow-up of fetal outcome with comparison control groups. Am J Gastroenterol 91 (1996) 348-354
37. Matheson I., Lunde P.K., and Bredesen J.E. Midazolam and nitrazepam in the maternity ward. milk concentrations and clinical effects. Br J Clin Pharmacol 30 (1990) 787-793
38. Stahl M.M., Saldeen P., and Vinge E. Reversal of fetal benzodiazepine intoxication using flumazenil. Br J Obstet Gynaecol 100 (1993) 185-188
39. Shin Y.K., Collea J.V., and Kim Y.D. The effect of glucagon on spontaneous contractility of isolated pregnant uterine muscle. Obstet Gynecol 88 (1996) 867-871
40. Rayburn W., Piehl E., Sanfield J., and Compton A. Reversing severe hypoglycemia during pregnancy with glucagon therapy. Am J Perinatol 4 (1987) 259-261
41. Czeizel A.E., Rockenbauer M., Sorensen H.T., and Olsen J. A population-based case-control teratologic study of ampicillin treatment during pregnancy. Am J Obstet Gynecol 185 (2001) 140-147
42. Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy Perinatol 5 (1984) 57-60
43. Czeizel A.E., Rockenbauer M., Olsen J., and Sorensen H.T. A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scand J Infect Dis 32 (2000) 309-313
44. Celiloglu M., Celiker S., Guven H., Tuncok Y., Demir N., and Erten O. Gentamicin excretion and uptake from breast milk by nursing infants. Obstet Gynecol 84 (1994) 263-265
45. Nardulli G., Limongi F., Sue G., Zapata L., and Bompart I. [Use of polyethylene glycol in the treatment of puerperal constipation]. G. E. N. 49 (1995) 224-226
46. Rimensberger P., Schubiger G., and Willi U. Connatal rickets following repeated administration of phosphate enemas in pregnancy. a case report. Eur J Pediatr 151 (1992) 54-56
47. Morrison J.C., Boyd M., Friedman B.I., Bucovaz E.T., Whybrew W.D., Koury D.N., Wiser W.L., and Fish S.A. The effects of Renografin-60 on the fetal thyroid. Obstet Gynecol 42 (1973) 99-103
48. Sorensen H.T., Nielsen G.L., Christensen K., Tage-Jensen U., Ekbom A., Baron J., and The Euromap study group. Birth outcome following maternal use of metoclopramide. Br J Clin Pharmacol 49 (2000) 264-268
49. Berkovitch M., Mazzota P., Greenberg R., Elbirt D., Addis A., Schuler-Faccini L., Merlob P., Arnon J., Stahl B., Magee L., Moretti M., and Ornoy A. Metoclopramide for nausea and vomiting of pregnancy. a prospective multicenter international study. Am J Perinatol 19 (2002) 311-316
50. Vella L., Francis D., Houlton P., and Reynolds F. Comparison of the antiemetics metoclopramide and promethazine in labour. Br Med J (Clin Res Ed) 290 (1985) 1173-1175
51. Breslow S., Belafsky H.A., Shangold J.E., Hirsch L.M., and Stahl M.B. Antiemetic effect of trimethobenzamide in pregnant patients. Clin Otorinolaringoiatr 8 (1961) 2153-2155
52. Miklovich L., and van den Berg B.J. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 125 (1976) 244-248
53. Winters H.S. Antiemetics in nausea and vomiting of pregnancy. Obstet Gynecol 18 (1961) 753-756
54. Sullivan C.A., Johnson C.A., Roach H., Martin R.W., Stewart D.K., and Morrison J.C. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 174 (1996) 1565-1568
55. Einarson A., Maltepe C., Navioz Y., Kennedy D., Tan M.P., and Koren G. The safety of ondansetron for nausea and vomiting of pregnancy. a prospective comparative study. BJOG 111 (2004) 940-943
56. Kytril [package insert] (1997), SmithKline Beecham, Philadelphia, PA
57. Ching C.K., and Lam S.K. Antacids. Indications and limitations. Drugs 47 (1994) 305-317
58. Witter F.R., King T.M., and Blake D.A. The effects of chronic gastrointestinal medication on the fetus and neonate. Obstet Gynecol 58 (1981) 79S-84S
59. McGuinness B., and Logan J.I. Milk alkali syndrome. Ulster Med J 71 (2002) 132-135
60. Ranchet G., Gangemi O., and Petrone M. Sucralfate in the treatment of gravid pyrosis. G Ital Ostericia Ginecol 12 (1990) 1-16
61. Kallen B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 105 (1998) 877-881
62. Ruigomez A., Garcia Rodriguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L., Wallander M.A., and Johansson S. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 150 (1999) 476-481
63. Larson J.D., Patatanian E., Miner Jr. P.B., Rayburn W.F., and Robinson M.G. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol 90 (1997) 83-87
64. Magee L.A., Inocencion G., Kamboj L., Rosetti F., and Koren G. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. Dig Dis Sci 41 (1996) 1145-1149
65. Garbis H., Elefant E., Diav-Citrin O., Mastroiacovo P., Schaefer C., Vial T., Clementi M., Valti E., McElhatton P., Smorlesi C., Rodriguez E.P., Robert-Gnansia E., Merlob P., Peiker G., Pexieder T., Schueler L., Ritvanen A., and Mathieu-Nolf M. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. Reprod Toxicol 19 (2005) 453-458
66. Morton D.M. Pharmacology and toxicology of nizatidine. Scand J Gastroenterol Suppl 136 (1987) 1-8
67. Sankaran K., Yeboah E., Bingham W.T., and Ninan A. Use of metoclopramide in preterm infants. Dev Pharmacol Ther 5 (1982) 114-119
68. Bailey B., Addis A., Lee A., Sanghvi K., Mastroiacovo P., Mazzone T., Bonati M., Paolini C., Garbis H., Val T., De Souza C.F., Matsui D., Schechtman A.S., Conover B., Lau M., and Koren G. Cisapride use during human pregnancy. a prospective, controlled multicenter study. Dig Dis Sci 42 (1997) 1848-1852
69. Prilosec [package insert] (2001), AstraZeneca, Wilmington, DE
70. Kallen B.A. Use of omeprazole during pregnancy-no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 96 (2001) 63-68
71. Lalkin A., Loebstein R., Addis A., Ramezani-Namin F., Mastroiacovo P., Mazzone T., Vial T., Bonati M., and Koren G. The safety of omeprazole during pregnancy. a multicenter prospective controlled study. Am J Obstet Gynecol 179 (1998) 727-730
72. Diav-Citrin O., Arnon J., Shechtman S., Schaefer C., van Tonningen M.R., Clementi M., De Santis M., Robert-Gnansia E., Valti E., Malm H., and Ornoy A. The safety of proton pump inhibitors in pregnancy. a multicentre prospective controlled study. Aliment Pharmacol Ther 21 (2005) 269-275
73. Wilton L.V., Pearce G.L., Martin R.M., Mackay F.J., and Mann R.D. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 105 (1998) 882-889
74. Nielsen G.L., Sorensen H.T., Thulstrup A.M., Tage-Jensen U., Olesen C., and Ekbom A. The safety of proton pump inhibitors in pregnancy. Aliment Pharmacol Ther 13 (1999) 1085-1089
75. Jepsen P., Skriver M.V., Floyd A., Lipworth L., Schonheyder H.C., and Sorensen H.T. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. Br J Clin Pharmacol 55 (2003) 216-221
76. Witt A., Sommer E.M., Cichna M., Postlbauer K., Widhalm A., Gregor H., and Reisenberger K. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol 188 (2003) 816-819
77. Einarson A., Phillips E., Mawji F., D'Alimonte D., Schick B., Addis A., Mastroiacova P., Mazzone T., Matsui D., and Koren G. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 15 (1998) 523-525
78. Drinkard C.R., Shatin D., and Clouse J. Postmarketing surveillance of medications and pregnancy outcomes. clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 9 (2000) 549-556
79. Sedlmayr T., Peters F., Raasch W., and Kees F. [Clarithromycin, a new macrolide antibiotic. Effectiveness in puerperal infections and pharmacokinetics in breast milk]. Geburtshilfe Frauenheilkd 53 (1993) 488-491
80. James L.F., Lazar V.A., and Binns W. Effects of sublethal doses of certain minerals on pregnant ewes and fetal development. Am J Vet Res 27 (1966) 132-135
81. Ridgway L.P., and Karnofsky D.A. The effects of metals on the chick embryo. toxicity and production of abnormalities in development. Ann N Y Acad Sci 55 (1952) 203-215
82. Lione A. Nonprescription drugs as a source of aluminum, bismuth, and iodine during pregnancy. Reprod Toxicol 1 (1987) 243-252
83. Luiten E.J., Hop W.C., Lange J.F., and Bruining H.A. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 222 (1995) 57-65
84. Loebstein R., Addis A., Ho E., Andreou R., Sage S., Donnenfeld A.E., Schick B., Bonati M., Moretti M., Lalkin A., Pastuszak A., and Koren G. Pregnancy outcome following gestational exposure to fluoroquinolones. a multicenter prospective controlled study. Antimicrob Agents Chemother 42 (1998) 1336-1339
85. Larsen H., Nielsen G.L., Schonheyder H.C., Olesen C., and Sorensen H.T. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents 18 (2001) 259-262
86. Moudgal V.V., and Sobel J.D. Antifungal drugs in pregnancy. a review. Expert Opin Drug Saf 2 (2003) 475-483
87. Dinsmoor M.J. Imipenem-cilastatin. Obstet Gynecol Clin North Am 19 (1992) 475-482
88. Heikkila A., Renkonen O.V., and Erkkola R. Pharmacokinetics and transplacental passage of imipenem during pregnancy. Antimicrob Agents Chemother 36 (1992) 2652-2655
89. Wunsch M.J., Stanard V., and Schnoll S.H. Treatment of pain in pregnancy. Clin J Pain 19 (2003) 148-155
90. Fischer G., Johnson R.E., Eder H., Jagsch R., Peternell A., Weninger M., Langer M., and Aschauer H.N. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 95 (2000) 239-244
91. Odegaard I., Stray-Pedersen B., Hallberg K., Haanaes O.C., Storrosten O.T., and Johannesson M. Maternal and fetal morbidity in pregnancies of Norwegian and Swedish women with cystic fibrosis. Acta Obstet Gynecol Scand 81 (2002) 698-705
92. Michel S.H., and Mueller D.H. Impact of lactation on women with cystic fibrosis and their infants. a review of five cases. J Am Diet Assoc 94 (1994) 159-165
93. Lu E.J., Curet M.J., El-Sayed Y.Y., and Kirkwood K.S. Medical versus surgical management of biliary tract disease in pregnancy. Am J Surg 188 (2004) 755-759
94. Ramin K.D., and Ramsey P.S. Disease of the gallbladder and pancreas in pregnancy. Obstet Gynecol Clin North Am 28 (2001) 571-580
95. Hempfling W., Dilger K., and Beuers U. Systematic review. ursodeoxycholic acid-adverse effects and drug interactions. Aliment Pharmacol Ther 18 (2003) 963-972
96. Christensen K.L., Andersen B.N., and Vilstrup H. [Primary sclerosing cholangitis with itching treated during pregnancy with ursodeoxycholic acid]. Ugeskr Laeger 159 (1997) 7151-7153
97. Gossard A.A., and Lindor K.D. Pregnancy in a patient with primary sclerosing cholangitis. J Clin Gastroenterol 35 (2002) 353-355
98. Poupon R., Chretien Y., Chazouilleres O., and Poupon R.E. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 42 (2005) 418-419
99. Palma J., Reyes H., Ribalta J., Hernandez I., Sandoval L., Almuna R., Liepins J., Lira F., Sedano M., Silva O., Toha D., and Silva J.J. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy. a randomized, double-blind study controlled with placebo. J Hepatol 27 (1997) 1022-1028
100. Magriples U. Hepatitis in pregnancy. Semin Perinatol 22 (1998) 112-117
101. Jonas M.M., Reddy R.K., DeMedina M., and Schiff E.R. Hepatitis B infection in a large municipal obstetrical population. characterization and prevention of perinatal transmission. Am J Gastroenterol 85 (1990) 277-280
102. Su G.G., Pan K.H., Zhao N.F., Fang S.H., Yang D.H., and Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 10 (2004) 910-912
103. van Zonneveld M., van Nunen A.B., Niesters H.G., de Man R.A., Schalm S.W., and Janssen H.L. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 10 (2003) 294-297
104. Antiretroviral Pregnancy Registry. The Antiretroviral Pregnancy Registry for abacavir, amprenavir, delavirdine, didanosine, efavirenz, indinavir, lamivudine, lamivudine/zidovudine, nelfinavir, nevirapine, ritonavir, saquinavir, saquinavir mesylate, stavudine, zalcitavine, zidovudine, Interim report 1 January 1989 though 31 July 2000. Antiretroviral Pregnancy Registry (2000) 1-55
105. Moodley J., Moodley D., Pillay K., Coovadia H., Saba J., van Leeuwen R., Goodwin C., Harrigan P.R., Moore K.H., Stone C., Plumb R., and Johnson M.A. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 178 (1998) 1327-1333
106. Chard T. Interferon in pregnancy. J Dev Physiol 11 (1989) 271-276
107. Hiratsuka M., Minakami H., Koshizuka S., and Sato I. Administration of interferon-alpha during pregnancy. effects on fetus. J Perinat Med 28 (2000) 372-376
108. Ozaslan E., Yilmaz R., Simsek H., and Tatar G. Interferon therapy for acute hepatitis C during pregnancy. Ann Pharmacother 36 (2002) 1715-1718
109. Rebetol [package insert] (2004), Schering, Kenilworth, NJ
110. Scheinberg I.H., and Sternlieb I. Pregnancy in penicillamine-treated patients with Wilson's disease. N Engl J Med 293 (1975) 1300-1302
111. Marecek Z., and Graf M. Pregnancy in penicillamine-treated patients with Wilson's disease. (letter). N Engl J Med 295 (1976) 841-842
112. Sinha S., Taly A.B., Prashanth L.K., Arunodaya G.R., and Swamy H.S. Successful pregnancies and abortions in symptomatic and asymptomatic Wilson's disease. J Neurol Sci 217 (2004) 37-40
113. Walshe J.M. The management of pregnancy in Wilson's disease treated with trientine. Q J Med 58 (1986) 81-87
114. Janczewska I., Olsson R., Hultcrantz R., and Broome U. Pregnancy in patients with primary sclerosing cholangitis. Liver 16 (1996) 326-330
115. Korkut E., Kisacik B., Akcan Y., Belenli O., Bicik Z., and Yucel O. Two successive pregnancies after ursodeoxycholic acid therapy in a previously infertile woman with antimitochondrial antibody-negative primary biliary cirrhosis. Fertil Steril 83 (2005) 761-763
116. Kondrackiene J., Beuers U., and Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129 (2005) 894-901
117. Pruyn S.C., Phelan J.P., and Buchanan G.C. Long-term propranolol therapy in pregnancy. maternal and fetal outcome. Am J Obstet Gynecol 135 (1979) 485-489
118. Fox R.E., Marx C., and Stark A.R. Neonatal effects of maternal nadolol therapy. Am J Obstet Gynecol 152 (1985) 1045-1046
119. Armenti V.T., Radomski J.S., Moritz M.J., Gaughan W.J., McGrory C.H., and Coscia L.A. Report from the National Transplantation Pregnancy Registry (NTPR). outcomes of pregnancy after transplantation. Clin Transpl (2003) 131-141
120. Bar Oz B., Hackman R., Einarson T., and Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy. a meta-analysis. Transplantation 71 (2001) 1051-1055
121. Nagy S., Bush M.C., Berkowitz R., Fishbein T.M., and Gomez-Lobo V. Pregnancy outcome in liver transplant recipients. Obstet Gynecol 102 (2003) 121-128
122. Jain A., Venkataramanan R., Fung J.J., Gartner J.C., Lever J., Balan V., Warty V., and Starzl T.E. Pregnancy after liver transplantation under tacrolimus. Transplantation 64 (1997) 559-565
123. Kainz A., Harabacz I., Cowlrick I.S., Gadgil S., and Hagiwara D. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int 13 Suppl 1 (2000) S299-S300
124. Jain A.B., Reyes J., Marcos A., Mazariegos G., Eghtesad B., Fontes P.A., Cacciarelli T.V., Marsh J.W., de Vera M.E., Rafail A., Starzl T.E., and Fung J.J. Pregnancy after liver transplantation with tacrolimus immunosuppression. a single center's experience update at 13 years. Transplantation 76 (2003) 827-832
125. Jankowska I., Oldakowska-Jedynak U., Jabiry-Zieniewicz Z., Cyganek A., Pawlowska J., Teisseyre M., Kalicinski P., Markiewicz M., Paczek L., and Socha J. Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient. Transplant Proc 36 (2004) 3232-3233
126. Le Ray C., Coulomb A., Elefant E., Frydman R., and Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation. a case of major fetal malformations. Obstet Gynecol 103 (2004) 1091-1094
127. Hasler W.L. The irritable bowel syndrome during pregnancy. Gastroenterol Clin North Am 32 (2003) 385-406 viii
128. Tytgat G.N., Heading R.C., Muller-Lissner S., Kamm M.A., Scholmerich J., Berstad A., Fried M., Chaussade S., Jewell D., and Briggs A. Contemporary understanding and management of reflux and constipation in the general population and pregnancy. a consensus meeting. Aliment Pharmacol Ther 18 (2003) 291-301
129. Attar A., Lemann M., Ferguson A., Halphen M., Boutron M.C., Flourie B., Alix E., Salmeron M., Guillemot F., Chaussade S., Menard A.M., Moreau J., Naudin G., and Barthet M. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 44 (1999) 226-230
130. Cameron B.D., Phillips M.W., and Fenerty C.A. Milk transfer of rhein in the rhesus monkey. Pharmacology 36 Suppl 1 (1988) 221-225
131. Sicuranza G.B., and Figueroa R. Uterine rupture associated with castor oil ingestion. J Matern Fetal Neonatal Med 13 (2003) 133-134
132. Einarson A., Mastroiacovo P., Arnon J., Ornoy A., Addis A., Malm H., and Koren G. Prospective, controlled, multicentre study of loperamide in pregnancy. Can J Gastroenterol 14 (2000) 185-187
133. Black R.A., and Hill D.A. Over-the-counter medications in pregnancy. Am Fam Physician 67 (2003) 2517-2524
134. Jenkins J.K., and Boothby L.A. Treatment of itching associated with intrahepatic cholestasis of pregnancy. Ann Pharmacother 36 (2002) 1462-1465
135. Patterson E.C., and Staszak D.J. Effects of geophagia (kaolin ingestion) on the maternal blood and embryonic development in the pregnant rat. J Nutr 107 (1977) 2020-2025
136. Collins E. Maternal and fetal effects of acetaminophen and salicylates in pregnancy. Obstet Gynecol 58 (1981) 57S-62S
137. Chun-Fai-Chan B., Koren G., Fayez I., Kalra S., Voyer-Lavigne S., Boshier A., Shakir S., and Einarson A. Pregnancy outcome of women exposed to bupropion during pregnancy. a prospective comparative study. Am J Obstet Gynecol 192 (2005) 932-936
138. Einarson T.R., and Einarson A. Newer antidepressants in pregnancy and rates of major malformations. a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 14 (2005) 823-827
139. GlaxoSmithKline. Study EPIP083. GSK medicine: bupropion and paroxetine. Epidemiology study: preliminary report on bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformation. Available at: http://ctr.gsk.co.uk/summary/paroxetine/epip083.pdf. Accessed October 26, 2005.
140. Williams M., and Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ 173 (2005) 1320-1321
141. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 158 (2004) 312-316
142. Kulin N.A., Pastuszak A., Sage S.R., Schick-Boschetto B., Spivey G., Feldkamp M., Ormond K., Matsui D., Stein-Schechman A.K., Cook L., Brochu J., Rieder M., and Koren G. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. a prospective controlled multicenter study. JAMA 279 (1998) 609-610
143. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., and Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335 (1996) 1010-1015
144. Hendrick V., Smith L.M., Suri R., Hwang S., Haynes D., and Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 188 (2003) 812-815
145. Sanz E.J., De-las-Cuevas C., Kiuru A., Bate A., and Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome. a database analysis. Lancet 365 (2005) 482-487
146. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 28 (2005) 137-152
147. McKeigue P.M., Lamm S.H., Linn S., and Kutcher J.S. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology 50 (1994) 27-37
148. Guerrant R.L., Van Gilder T., Steiner T.S., Thielman N.M., Slutsker L., Tauxe R.V., Hennessy T., Griffin P.M., DuPont H., Sack R.B., Tarr P., Neill M., Nachamkin I., Reller L.B., Osterholm M.T., Bennish M.L., and Pickering L.K. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32 (2001) 331-351
149. Albenza [package insert] (2001), SmithKline Beecham Pharmaceuticals, Philadelphia, PA
150. Gyapong J.O., Chinbuah M.A., and Gyapong M. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Trop Med Int Health 8 (2003) 1093-1101
151. Torlesse H., and Hodges M. Albendazole therapy and reduced decline in haemoglobin concentration during pregnancy (Sierra Leone). Trans R Soc Trop Med Hyg 95 (2001) 195-201
152. Torlesse H., and Hodges M. Anthelminthic treatment and haemoglobin concentrations during pregnancy. Lancet 356 (2000) 1083
153. Niebyl J.R. Antibiotics and other anti-infective agents in pregnancy and lactation. Am J Perinatol 20 (2003) 405-414
154. Kacmar J., Cheh E., Montagno A., and Peipert J.F. A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy. Infect Dis Obstet Gynecol 9 (2001) 197-202
155. Kigozi G.G., Brahmbhatt H., Wabwire-Mangen F., Wawer M.J., Serwadda D., Sewankambo N., and Gray R.H. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy. a subanalysis of a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 189 (2003) 1398-1400
156. Kline A.H., Blattner R.J., and Lunin M. Transplacental effect of tetracyclines of teeth. JAMA 188 (1964) 178-180
157. Czeizel A.E., and Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 89 (1997) 524-528
158. Heinonen O.P., Slone D., and Shaprio S. Birth defects and drug in pregnancy (1977), Publishing Sciences Group, Littleton, MA
159. Burtin P., Taddio A., Ariburnu O., Einarson T.R., and Koren G. Safety of metronidazole in pregnancy. a meta-analysis. Am J Obstet Gynecol 172 (1995) 525-529
160. Caro-Paton T., Carvajal A., Martin de Diego I., Martin-Arias L.H., Alvarez Requejo A., and Rodriguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44 (1997) 179-182
161. Piper J.M., Mitchel E.F., and Ray W.A. Prenatal use of metronidazole and birth defects. no association. Obstet Gynecol 82 (1993) 348-352
162. Sorensen H.T., Larsen H., Jensen E.S., Thulstrup A.M., Schonheyder H.C., Nielsen G.L., and Czeizel A. Safety of metronidazole during pregnancy. a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrob Chemother 44 (1999) 854-856
163. Diav-Citrin O., Shechtman S., Gotteiner T., Arnon J., and Ornoy A. Pregnancy outcome after gestational exposure to metronidazole. a prospective controlled cohort study. Teratology 63 (2001) 186-192
164. Czeizel A.E., and Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 105 (1998) 322-327
165. Bertoli D., and Borelli G. Fertility study of rifaximin (L/105) in rats. Chemioterapia 5 (1986) 204-207
166. Bertoli D., and Borelli G. [Teratogenic action of Rifaximin in the rat and rabbit and its effect on perinatal development in the rat]. Boll Soc Ital Biol Sper 60 (1984) 1079-1085
167. Xifaxan [package insert] (2005), Salix Pharmaceuticals, Morrisville, NC
168. Karhunen M. Placental transfer of metronidazole and tinidazole in early human pregnancy after a single infusion. Br J Clin Pharmacol 18 (1984) 254-257
169. Czeizel A.E., Kazy Z., and Vargha P. Oral tinidazole treatment during pregnancy and teratogenesis. Int J Gynaecol Obstet 83 (2003) 305-306
170. Evaldson G.R., Lindgren S., Nord C.E., and Rane A.T. Tinidazole milk excretion and pharmacokinetics in lactating women. Br J Clin Pharmacol 19 (1985) 503-507
171. Czeizel A.E., Rockenbauer M., Sorensen H.T., and Olsen J. The teratogenic risk of trimethoprim-sulfonamides. a population based case-control study. Reprod Toxicol 15 (2001) 637-646
172. Vancocin [package insert] (2000), Eli Lilly, Indianapolis, IN
173. Reyes M.P., Ostrea Jr. E.M., Cabinian A.E., Schmitt C., and Rintelmann W. Vancomycin during pregnancy. does it cause hearing loss or nephrotoxicity in the infant?. Am J Obstet Gynecol 161 (1989) 977-981
174. Woolfson K., Cohen Z., and McLeod R.S. Crohn's disease and pregnancy. Dis Colon Rectum 33 (1990) 869-873
175. Craxi A., and Pagliarello F. Possible embryotoxicity of sulfasalazine. Arch Intern Med 140 (1980) 1674
176. Hoo J.J., Hadro T.A., and Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med 318 (1988) 1128
177. Newman N.M., and Correy J.F. Possible teratogenicity of sulphasalazine. Med J Aust 1 (1983) 528-529
178. Mogadam M., Dobbins III W.O., Korelitz B.I., and Ahmed S.W. Pregnancy in inflammatory bowel disease. effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 80 (1981) 72-76
179. Norgard B., Czeizel A.E., Rockenbauer M., Olsen J., and Sorensen H.T. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15 (2001) 483-486
180. Esbjorner E., Jarnerot G., and Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 76 (1987) 137-142
181. Levi A.J., Fisher A.M., Hughes L., and Hendry W.F. Male infertility due to sulphasalazine. Lancet 2 (1979) 276-278
182. Toovey S., Hudson E., Hendry W.F., and Levi A.J. Sulphasalazine and male infertility. reversibility and possible mechanism. Gut 22 (1981) 445-451
183. Chatzinoff M., Guarino J.M., Corson S.L., Batzer F.R., and Friedman L.S. Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas. Dig Dis Sci 33 (1988) 108-110
184. Kjaergaard N., Christensen L.A., Lauritsen J.G., Rasmussen S.N., and Hansen S.H. Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis. Scand J Gastroenterol 24 (1989) 891-896
185. Moody G.A., Probert C., Jayanthi V., and Mayberry J.F. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorectal Dis 12 (1997) 220-224
186. Habal F.M., Hui G., and Greenberg G.R. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy. safety and clinical course. Gastroenterology 105 (1993) 1057-1060
187. Marteau P., Tennenbaum R., Elefant E., Lemann M., and Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 12 (1998) 1101-1108
188. Trallori G., d'Albasio G., Bardazzi G., Bonanomi A.G., Amorosi A., Del Carlo P., Palli D., Galli M., and Pacini F. 5-Aminosalicylic acid in pregnancy. clinical report. Ital J Gastroenterol 26 (1994) 75-78
189. Diav-Citrin O., Park Y.H., Veerasuntharam G., Polachek H., Bologa M., Pastuszak A., and Koren G. The safety of mesalamine in human pregnancy. a prospective controlled cohort study. Gastroenterology 114 (1998) 23-28
190. Norgard B., Fonager K., Pedersen L., Jacobsen B.A., and Sorensen H.T. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy. a Danish cohort study. Gut 52 (2003) 243-247
191. Nelis G.F. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet 1 (1989) 383
192. Czeizel A.E., Rockenbauer M., Sorensen H.T., and Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities. a population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol 97 (2001) 188-192
193. Berkovitch M., Diav-Citrin O., Greenberg R., Cohen M., Bulkowstein M., Shechtman S., Bortnik O., Arnon J., and Ornoy A. First-trimester exposure to amoxycillin/clavulanic acid. a prospective, controlled study. Br J Clin Pharmacol 58 (2004) 298-302
194. Rodriguez-Pinilla E., and Martinez-Frias M.L. Corticosteroids during pregnancy and oral clefts. a case-control study. Teratology 58 (1998) 2-5
195. Carmichael S.L., and Shaw G.M. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 86 (1999) 242-244
196. Park-Wyllie L., Mazzotta P., Pastuszak A., Moretti M.E., Beique L., Hunnisett L., Friesen M.H., Jacobson S., Kasapinovic S., Chang D., Diav-Citrin O., Chitayat D., Nulman I., Einarson T.R., and Koren G. Birth defects after maternal exposure to corticosteroids. prospective cohort study and meta-analysis of epidemiological studies. Teratology 62 (2000) 385-392
197. Gur C., Diav-Citrin O., Shechtman S., Arnon J., and Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids. a prospective controlled study. Reprod Toxicol 18 (2004) 93-101
198. Armenti V.T., Moritz M.J., Cardonick E.H., and Davison J.M. Immunosuppression in pregnancy. choices for infant and maternal health. Drugs 62 (2002) 2361-2375
199. Gluck P.A., and Gluck J.C. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. Curr Med Res Opin 21 (2005) 1075-1084
200. Norjavaara E., and de Verdier M.G. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol 111 (2003) 736-742
201. Patlas N., Golomb G., Yaffe P., Pinto T., Breuer E., and Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60 (1999) 68-73
202. Del Campo M., Kosaki K., Bennett F.C., and Jones K.L. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 60 (1999) 10-12
203. French A.E., and Koren G. Effect of methotrexate on male fertility. Can Fam Physician 49 (2003) 577-578
204. Polifka J.E., and Friedman J.M. Teratogen update. azathioprine and 6-mercaptopurine. Teratology 65 (2002) 240-261
205. Saarikoski S., and Seppala M. Immunosuppression during pregnancy. transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 115 (1973) 1100-1106
206. Norgard B., Pedersen L., Fonager K., Rasmussen S.N., and Sorensen H.T. Azathioprine, mercaptopurine and birth outcome. a population-based cohort study. Aliment Pharmacol Ther 17 (2003) 827-834
207. Alstead E.M., Ritchie J.K., Lennard-Jones J.E., Farthing M.J., and Clark M.L. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 99 (1990) 443-446
208. Francella A., Dyan A., Bodian C., Rubin P., Chapman M., and Present D.H. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease. a retrospective cohort study. Gastroenterology 124 (2003) 9-17
209. Khan Z.H., Mayberry J.F., Spiers N., and Wicks A.C. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 62 (2000) 249-254
210. Moskovitz D.N., Bodian C., Chapman M.L., Marion J.F., Rubin P.H., Scherl E., and Present D.H. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99 (2004) 656-661
211. Bertschinger P., Himmelmann A., Risti B., and Follath F. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol 90 (1995) 330
212. Anderson J.B., Turner G.M., and Williamson R.C. Fulminant ulcerative colitis in late pregnancy and the puerperium. J R Soc Med 80 (1987) 492-494
213. Baumgart D.C., Sturm A., Wiedenmann B., and Dignass A.U. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 54 (2005) 1822-1823
214. Ehrenpreis E.D., Kane S.V., Cohen L.B., Cohen R.D., and Hanauer S.B. Thalidomide therapy for patients with refractory Crohn's disease. an open-label trial. Gastroenterology 117 (1999) 1271-1277
215. Thalomid [package insert] (2000), Celgene Corp, Summit, NJ
216. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., and Rutgeerts P. Maintenance infliximab for Crohn's disease. the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
217. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villiers W.J., Present D., Sands B.E., and Colombel J.F. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
218. Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 96 (2001) 2274-2275
219. James R.L., and Pearson L.L. Successful treatment of pregnancy-triggered Crohn's disease complicated by severe recurrent life-threatening gastrointestinal bleeding (abstr). Am J Gastroenterol 96 (2001) S295
220. Bank L., and Hunt B. Unexpected dramatic clinical response of psoriasis lesions and unexpected pregnancy in an infertile patient in response to treatment with anti-tumor necrosis factor monoclonal antibody for Crohn's disease (abstr). Am J Gastroenterol 97 (2002) S260
221. Burt M.J., Frizelle F.A., and Barbezat G.O. Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody). J Gastroenterol Hepatol 18 (2003) 465-466
222. Lichtenstein G., Cohen R.D., Feagan B.G., et al. Safety of infliximab in Crohn's disease. data from the 5000-patient TREAT Registry. (abstr). Gastroenterology 126 (2004) A54
223. Katz J.A., Antoni C., Keenan G.F., Smith D.E., Jacobs S.J., and Lichtenstein G.R. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 99 (2004) 2385-2392
224. Mahadevan U., Kane S., Sandborn W.J., Cohen R.D., Hanson K., Terdiman J.P., and Binion D.G. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 21 (2005) 733-738
225. Vasiliauskas E., Barry M., Dubinsky M., et al. High serum levels of infliximab detected in the newborn of a mother receiving infliximab during pregnancy. (abstr). Gastroenterology 128 (2005) P33
226. Peltier M., James D., Ford J., et al. Infliximab levels in breast-milk of a nursing Crohn's patient. (abstr). Am J Gastroenterol 96 (2001) P258
227. Hanauer S.B., Lukas M., MacIntosh D., et al. A randomized, double-blind, placebo controlled trial of the human anti-TNF alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. (abstr). Gastroenterology 127 (2004) 332
228. Vesga L., Terdiman J.P., and Mahadevan U. Adalimumab use in pregnancy. Gut 54 (2005) 890
229. Olsen S.F., Sorensen J.D., Secher N.J., Hedegaard M., Henriksen T.B., Hansen H.S., and Grant A. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet 339 (1992) 1003-1007
230. Rossi E., and Costa M. Fish oil derivatives as a prophylaxis of recurrent miscarriage associated with antiphospholipid antibodies (APL). a pilot study. Lupus 2 (1993) 319-323
231. Food and Drug Administration. Regulations 44 (1980) 37434-37467